The Value of Complementary Right-sided Hemicolectomy for Pediatric Patients With High-risk Neuroendocrine Tumors (NETs) of the Appendix; Towards the Development of an (Inter-) National Consensus Guideline for the Pediatric Population.
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Recurrence rate
研究概览
简要总结
The goal of this observational study is to investigate the beneficial value of complementary surgery for appendiceal neuro-endocrine tumours in children.
.
详细描述
Aim Current guidelines recommend complementary right-sided hemicolectomy for high-risk (pT2(with risk factors)/pT3) neuro-endocrine tumors (NET) of the appendix (based on adult studies). In contrast to adults, high-risk NET of the appendix in children seems to be a relatively benign disease with high disease-free survival (100% versus 70-80% in adults), but high quality data are lacking. Therefore these recommendations are now being questioned. We aim to investigate the value of complementary right-sided hemicolectomy for children with high-risk NET of the appendix. Ultimately leading to the development of a consensus guideline and solid information for patients/parents.
Plan of investigation In order to generate big data, an international historical cohort study is planned to compare complementary right-sided hemicolectomy with appendectomy alone for children with high-risk NET of the appendix. Results will be CONFIDENTIAL used by an international expert group to formulate treatment recommendations. Subsequently, these recommendations will be tested in an international Delphi study in order to develop a consensus guideline on the treatment of pediatric high-risk NET of the appendix.
Expected results The cohort study will generate high quality information on overall/disease-free survival, recurrence, complications, costs, and hr-QoL. Recommendations made will be tested in a Delphi study; not only on the beneficial value of complementary right-sided hemicolectomy, but also on follow-up protocols and preoperative work-up. Ultimately, an international consensus guideline that redefines low-risk and high-risk NET of the appendix will be developed, leading to global de-escalation and uniformity of treatment.
Relevance for childhood cancer Results are relevant for pediatric oncologists/surgeons/gastro-enterologists across the world, as redefining low-risk and high-risk patient groups, will lead to de-escalation of treatment. Furthermore, QoL of child and parents can be improved by reducing exposure to complications after complementary right-sided hemicolectomy, and by reducing the fear of recurrence by obtaining high-quality data to accurately inform patients and parents.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- — 至 17 Years(Child)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients that were treated for an appendiceal NET before the age of 18 years old
- •Time period: 1990-2020
排除标准
- •Other appendiceal malignancies/tumours, for example:
- •goblet cell carcinoma
- •adenocarcinoma
- •neuroendocrine carcinoma
结局指标
主要结局
Recurrence rate
时间窗: cross-sectional design. follow-up will be done in 2023/2024
defined as histopathologically proven metastasis/residual tumor at appendiceal stump of NET after a disease free period
Disease free survival rate
时间窗: cross-sectional design. follow-up will be done in 2023/2024
defined as alive and free of recurrence of NET at telephone follow-up performed for this study purpose
次要结局
- Complications directly related to primary and secondary treatment divided into major and minor complications according to Clavien-dindo.(cross-sectional design. follow-up will be done in 2023/2024)
- Number of hospital readmission for complications related to treatment of NET(cross-sectional design. follow-up will be done in 2023/2024)
- number of imaging studies performed for follow-up of NET(cross-sectional design. follow-up will be done in 2023/2024)
- Length of hospital stay(cross-sectional design. follow-up will be done in 2023/2024)
- Number of outpatient check-ups(regular visits / telephone call) for follow-up of NET(cross-sectional design. follow-up will be done in 2023/2024)
- Overall survival rate(cross-sectional design. follow-up will be done in 2023/2024)
- Health related Quality of Life at follow-up moment for this study(cross-sectional design. follow-up will be done in 2023/2024)
研究者
Ramon Gorter
Principal investigator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
